SACT consent forms on Cancer Research UK website

 

National Systemic Anti-Cancer Therapy (SACT) consent forms – for urology (germ cell), breast and oesophago-gastric cancers published.

 

Regimen-specific consent forms for the following tumour groups have been published on the Cancer Research UK website:

·         Breast cancer – 3 forms added

o   Palbociclib

o   Pertuzumab-Trastuzumab version-2

o   Ribociclib

 

·         Urology-Germ Cell cancers – 6 forms

 

·         Oesophago-gastric cancer – 1 form added

o   Capecitabine-Cisplatin+Radiotherapy

 

 

 

Please visit www.cruk.org/sact_consent to view and download the forms.  Other forms, national guidance on consent for SACT, and further information is also available via www.cruk.org/sact_consent.

 

Please do not hesitate to contact Victoria Fashina (Oncology Pharmacist – CRUK information lead, Guy’s and St. Thomas’ NHS Foundation Trust) if you have any queries: [email protected]

 

Victoria Fashina

12 April 2018

 

Latest News

By BOPA Committee on 3rd May 2025

Let’s Talk About SACT podcast has been featured in the TOP 40 pharmacology Podcasts worldwide

The BOPA podcast team (Michal Sladkowski, Chiara Creed and Eleanor Meerstadt) are thrilled to share that the Let’s Talk About SACT podcast has been featured in the TOP 40 pharmacology…

Read article
By BOPA Education & Training Subcommittee on 3rd May 2025

NEW eLearning module for Myeloma now live

Dear BOPA members,   The Education and Training subcommittee are pleased to announce that our new e-learning module for myeloma is now live on the BOPA website. The module can…

Read article
By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article